Research

Publications

Below you can find a list of our published research.

8892 results

Cited 34 times since 2016 (3.7 per year) source: EuropePMC

Open forum infectious diseases, Volume 3, Issue 4, 30 5 2016, Pages ofw178 Duration of Colonization With <i>Klebsiella pneumoniae</i> Carbapenemase-Producing Bacteria at Long-Term Acute Care Hospitals in Chicago, Illinois. Haverkate MR, Weiner S, Lolans K, Moore NM, Weinstein RA, Bonten MJ, Hayden MK, Bootsma MC

Background. High prevalence of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae has been reported in long-term acute care hospitals (LTACHs), in part because of frequent readmissions of colonized patients. Knowledge of the duration of colonization with KPC is essential to identify patients at risk of KPC colonization upon readmission and to make predictions on the effects of transmission control measures. Methods. We analyzed data on surveillance isolates that were collec... Abstract

Cited 26 times since 2016 (2.8 per year) source: EuropePMC

The Journal of thoracic and cardiovascular surgery, Volume 152, Issue 6, 28 4 2016, Pages 1572-1579.e3 Allografts in aortic position: Insights from a 27-year, single-center prospective study. Arabkhani B, Bekkers JA, Andrinopoulou ER, Roos-Hesselink JW, Takkenberg JJ, Bogers AJ

Objective: Over the past decades, the indication for allograft implantation in aortic position has evolved. The purpose of this study is to report long-term survival, allograft durability, and potential risk factors. Methods: Between 1987 and 2010, 353 patients underwent aortic valve replacements via allograft (92 subcoronary, 261 root replacement; 98% aortic allografts). Patient characteristics, survival, valve durability, and valve-related events were analyzed. Patients also were followed with... Abstract

Cited 252 times since 2016 (27.6 per year) source: EuropePMC

European journal of heart failure, Volume 19, Issue 1, 27 4 2016, Pages 9-42 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Barón-Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S, Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), Document Reviewers

Abstract

Cited 3 times since 2016 (0.3 per year) source: EuropePMC

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, Volume 90, Issue 1, 27 4 2016, Pages E1-E10 Anatomical and functional assessment of Tryton bifurcation stent before and after final kissing balloon dilatation: Evaluations by three-dimensional coronary angiography, optical coherence tomography imaging and fractional flow reserve. Pyxaras SA, Toth GG, Di Gioia G, Ughi GJ, Tu S, Rusinaru D, Adriaenssens T, Reiber JHC, Leon MB, Bax JJ, Wijns W

Objectives: To assess the anatomical and functional impact of final kissing balloon inflation (FKBI) after implantation of a dedicated bifurcation stent system. Background: Current evidence suggests clinical benefit of FKBI in patients undergoing bifurcation dilatation using the Tryton side branch stent (Tryton-SBS). We hypothesized that FKBI improves anatomical reconstruction and functional results of bifurcation treated by Tryton-SBS. Methods: An unselected group of patients with complex bifur... Abstract

Cited 3957 times since 2016 (432.7 per year) source: EuropePMC

European heart journal, Volume 37, Issue 38, 27 4 2016, Pages 2893-2962 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, ESC Scientific Document Group

Abstract

Cited 1119 times since 2016 (122.4 per year) source: EuropePMC

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 18, Issue 11, 27 4 2016, Pages 1609-1678 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K

Abstract

Cited 1646 times since 2016 (180 per year) source: EuropePMC

European heart journal, Volume 37, Issue 39, 27 4 2016, Pages 2999-3058 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group

Abstract

Cited 1656 times since 2016 (181 per year) source: EuropePMC

European heart journal, Volume 37, Issue 36, 26 4 2016, Pages 2768-2801 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, ESC Scientific Document Group

Abstract

Cited 8 times since 2016 (0.9 per year) source: EuropePMC

Congenital heart disease, Volume 12, Issue 1, 25 4 2016, Pages 32-39 Surgical outcome in pediatric patients with Ebstein's anomaly: A multicenter, long-term study. Geerdink LM, du Marchie Sarvaas GJ, Kuipers IM, Helbing WA, Delhaas T, Ter Heide H, Rozendaal L, de Korte CL, Singh SK, Ebels T, Hazekamp MG, Haas F, Bogers AJ, Kapusta L

Objective: Surgical outcomes of pediatric patients with Ebstein's anomaly are often described as part of all-age-inclusive series. Our objective is to focus on patients treated surgically in childhood (0-18 y). We study the intended treatment (biventricular or 1.5 ventricle repair or univentricular palliation), freedom from unplanned reoperation and survival of this specific age group, in a nationwide study. Design: Records of all Ebstein's anomaly patients born between 1980 and 2013 w... Abstract

Cited 125 times since 2016 (13.7 per year) source: EuropePMC

Angewandte Chemie (International ed. in English), Volume 55, Issue 40, 24 4 2016, Pages 12440-12444 Development of Light-Activated CRISPR Using Guide RNAs with Photocleavable Protectors. Jain PK, Ramanan V, Schepers AG, Dalvie NS, Panda A, Fleming HE, Bhatia SN

The ability to remotely trigger CRISPR/Cas9 activity would enable new strategies to study cellular events with greater precision and complexity. In this work, we have developed a method to photocage the activity of the guide RNA called "CRISPR-plus" (CRISPR-precise light-mediated unveiling of sgRNAs). The photoactivation capability of our CRISPR-plus method is compatible with the simultaneous targeting of multiple DNA sequences and supports numerous modifications that can enable guide... Abstract

Cited 23 times since 2016 (2.5 per year) source: EuropePMC

BMC sports science, medicine & rehabilitation, Volume 8, Issue 1, 23 4 2016, Pages 25 Exergaming (XBOX Kinect™) versus traditional gym-based exercise for postural control, flow and technology acceptance in healthy adults: a randomised controlled trial. Barry G, van Schaik P, MacSween A, Dixon J, Martin D

Background: The use of exergaming is a potential alternative to traditional methods of balance training, which can be repetitive and somewhat monotonous. The purpose of this study was to assess the effects of exergaming using XBOX Kinect™ versus traditional gym-based exercise with no virtual stimuli (TGB) on postural control, technology acceptance, flow experience and exercise intensity, in young healthy adults. Methods: Fifty healthy active adults (age: 33.8 ± 12.7 years, height: 172.9 ± 11.9 c... Abstract

Cited 29 times since 2016 (3.2 per year) source: EuropePMC

Journal of clinical pharmacology, Volume 57, Issue 2, 23 4 2016, Pages 235-246 CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. Zhu L, Brüggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, Sims K, Vakkalagadda B, Xu X, van Schaik RH, Burger DM, Bertz RJ

Voriconazole, a broad-spectrum triazole antifungal agent, is metabolized by cytochrome P450 (CYP) 2C19 and, to a lesser extent, by CYP3A. Genetic polymorphism of CYP2C19 not only plays a prominent role in its disposition but may also influence potential drug interactions with CYP450 modulators such as ritonavir. This study assessed 2-way drug interactions of voriconazole added on to ritonavir-boosted atazanavir in both CYP2C19 extensive-metabolizer (EM) and poor-metabolizer (PM) healthy subjects... Abstract

Angiology, Volume 68, Issue 6, 23 4 2016, Pages 519-527 Very Long-Term Follow-Up After Coronary Rotational Atherectomy: A Single-Center Experience. Tohamy A, Klomp M, Putter H, Youssef A, Shams-Eddin H, Abdelsabour M, Schalij MJ, Jukema JW

We assessed the very long-term follow-up of a large cohort of unselected patients treated with coronary rotational atherectomy (RA). All 143 patients who underwent RA at our institution from 2000 to 2013 and with complete baseline and follow-up information were analyzed in a retrospective manner. Major adverse cardiac events (MACE) were defined as the composite of target vessel revascularization (TVR), acute myocardial infarction, and all-cause mortality. The mean follow-up was 8.2 years. The 10... Abstract

Cited 23 times since 2016 (2.5 per year) source: EuropePMC

The American journal of cardiology, Volume 118, Issue 10, 23 4 2016, Pages 1533-1538 Comparison of Quantity of Calcific Deposits by Multidetector Computed Tomography in the Aortic Valve and Coronary Arteries. van Rosendael PJ, Kamperidis V, Kong WK, van Rosendael AR, Marsan NA, Bax JJ, Delgado V

The aim of this study was to compare the calcium burden of the aortic valve and coronary arteries with multidetector computed tomography (MDCT) in a propensity score-matched population of patients with a bicuspid versus a tricuspid aortic valve. From an ongoing clinical registry of patients who underwent MDCT, 70 patients with bicuspid aortic valve and 210 patients with tricuspid aortic valve were matched based on age, gender, cardiovascular risk factors, chest pain symptoms, and MDCT indication... Abstract

Cited 3 times since 2016 (0.3 per year) source: EuropePMC

Pharmacogenomics, Volume 17, Issue 14, 22 4 2016, Pages 1533-1545 Minimum information required for a DMET experiment reporting. Kumuthini J, Mbiyavanga M, Chimusa ER, Pathak J, Somervuo P, Van Schaik RH, Dolzan V, Mizzi C, Kalideen K, Ramesar RS, Macek M, Patrinos GP, Squassina A

Aim: To provide pharmacogenomics reporting guidelines, the information and tools required for reporting to public omic databases. Material & methods: For effective DMET data interpretation, sharing, interoperability, reproducibility and reporting, we propose the Minimum Information required for a DMET Experiment (MIDE) reporting. Results: MIDE provides reporting guidelines and describes the information required for reporting, data storage and data sharing in the form of XML. Conclusion: The... Abstract

Cited 23 times since 2016 (2.5 per year) source: EuropePMC

Infection and immunity, Volume 84, Issue 9, 19 3 2016, Pages 2524-2533 The Type IV Secretion System Effector Protein CirA Stimulates the GTPase Activity of RhoA and Is Required for Virulence in a Mouse Model of Coxiella burnetii Infection. Weber MM, Faris R, van Schaik EJ, McLachlan JT, Wright WU, Tellez A, Roman VA, Rowin K, Case ED, Luo ZQ, Samuel JE

Coxiella burnetii, the etiological agent of Q fever in humans, is an intracellular pathogen that replicates in an acidified parasitophorous vacuole derived from host lysosomes. Generation of this replicative compartment requires effectors delivered into the host cell by the Dot/Icm type IVb secretion system. Several effectors crucial for C. burnetii intracellular replication have been identified, but the host pathways coopted by these essential effectors are poorly defined, and very little is kn... Abstract

Cited 11 times since 2016 (1.2 per year) source: EuropePMC

The British journal of dermatology, Volume 175, Issue 6, 19 3 2016, Pages 1357-1360 Ulcerated infantile haemangiomas: the effect of the selective beta-blocker atenolol on wound healing. Ruitenberg G, Young-Afat DA, de Graaf M, Pasmans SG, Breugem CC

Abstract

Cited 2 times since 2016 (0.2 per year) source: EuropePMC

Clinical nutrition ESPEN, Volume 15, 18 3 2016, Pages 114-121 A protocol for sustained reduction of Total Parenteral Nutrition and cost savings by improvement of nutritional care in hospitals. van Schaik R, Van den Abeele K, Melsens G, Schepens P, Lanssens T, Vlaemynck B, Devisch M, Niewold TA

Background and aims: Malnutrition and the use of Total Parenteral Nutrition (TPN) contribute considerably to hospital costs. Recently, we reported on the introduction of malnutrition screening and monitoring of TPN use in our hospital, which resulted in a large (40%) reduction in TPN and improved quality of nutritional care in two years (2011/12). Here, we aimed to assure continuation of improved care by developing a detailed malnutrition screening and TPN use protocol involving instruction tool... Abstract

Cited 21 times since 2016 (2.3 per year) source: EuropePMC

Pharmacogenomics, Volume 17, Issue 14, 17 3 2016, Pages 1483-1490 Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, van Schaik RH, Mathijssen RH

Aim: Sorafenib-treated patients display a substantial variation in the incidence of toxicity. We aimed to investigate the association of genetic polymorphisms with observed toxicity on sorafenib. Patients & methods: We genotyped 114 patients that were treated with sorafenib at the Erasmus MC Cancer Institute, the Netherlands, for SLCO1B1, SLCO1B3, ABCC2, ABCG2, UGT1A1 and UGT1A9. Results: The UGT1A1 (rs8175347) polymorphism was associated with hyperbilirubinemia and treatment interruption. P... Abstract

Cited 228 times since 2016 (24.9 per year) source: EuropePMC

Circulation research, Volume 119, Issue 9, 16 3 2016, Pages 996-1003 RBM20 Regulates Circular RNA Production From the Titin Gene. Khan MA, Reckman YJ, Aufiero S, van den Hoogenhof MM, van der Made I, Beqqali A, Koolbergen DR, Rasmussen TB, van der Velden J, Creemers EE, Pinto YM

Rationale: RNA-binding motif protein 20 (RBM20) is essential for normal splicing of many cardiac genes, and loss of RBM20 causes dilated cardiomyopathy. Given its role in splicing, we hypothesized an important role for RBM20 in forming circular RNAs (circRNAs), a novel class of noncoding RNA molecules. Objective: To establish the role of RBM20 in the formation of circRNAs in the heart. Methods and results: Here, we performed circRNA profiling on ribosomal depleted RNA from human hearts and ident... Abstract